Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Rini Explores PD-1 Inhibition in Renal Cell Carcinoma

July 18th 2014

Development of Checkpoint Inhibitors for GU Cancers

July 18th 2014

Checkpoint Inhibition in Renal Cell Carcinoma

July 18th 2014

Utility of PD-L1 as a Biomarker in Bladder Cancer

July 18th 2014

Evolving Role of PD-L1 as a Biomarker

July 18th 2014

PD-L1 Immunotherapy in Bladder Cancer

July 18th 2014

Targeted Immunotherapy in Cancer

July 18th 2014

Future Role of Immunotherapy in Cancer

July 18th 2014

PD-L1 Inhibition With MPDL3280A in Bladder Cancer

July 18th 2014

Adjuvant Ipilimumab in High-Risk Melanoma

July 18th 2014

Checkpoint Inhibitor Combination Strategies

July 18th 2014

Future Role of Checkpoint Inhibitors in Melanoma

July 18th 2014

Checkpoint Inhibitors in Metastatic Melanoma

July 18th 2014

Introduction: Immunotherapy Research Milestones

July 18th 2014

Dabrafenib/Trametinib Extends OS Versus Vemurafenib in Phase III Melanoma Trial

July 18th 2014

A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis

Immunotherapy Branches Out

July 18th 2014

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

Vemurafenib/Cobimetinib Extends PFS in Phase III Melanoma Study

July 14th 2014

The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib significantly improved PFS compared with vemurafenib alone for patients with untreated BRAFV600-mutated advanced melanoma.

Dr. Puzanov on T-VEC in Combination with Ipilimumab for Melanoma Treatment

July 9th 2014

Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma.

Nivolumab, Alectinib Gain Approvals in Japan

July 7th 2014

The PD-1 inhibitor nivolumab and the second-generation ALK inhibitor alectinib have each gained their first approvals as treatments for patients in Japan.

Frontline Nivolumab Improves Survival in Phase III Melanoma Study

June 25th 2014

Frontline treatment with the anti-PD-1 agent nivolumab significantly extended overall survival when compared with dacarbazine for patients with metastatic or unresectable melanoma.